A Phase 4, Open-Label, Single-Dose Study to Evaluate Sunosi (Solriamfetol) Pharmacokinetics in Breast Milk and Plasma of Healthy Postpartum Women Following Oral Administration of Sunosi
Latest Information Update: 16 Apr 2023
At a glance
- Drugs Solriamfetol (Primary)
- Indications Hypersomnia
- Focus Pharmacokinetics
- Sponsors Jazz Pharmaceuticals Inc
- 28 Apr 2022 Status changed from recruiting to completed.
- 27 Sep 2021 Status changed from not yet recruiting to recruiting.
- 23 Aug 2021 New trial record